5970
E. Serrao et al. / Bioorg. Med. Chem. 21 (2013) 5963–5972
continuously stirred at rt for 8 h. Then the crude product was pre-
cipitated out when the pH was adjusted to 5 with 3 N HCl. The
solid was filtered and subsequently recrystallized from methanol
and ethyl acetate to give pale yellow solid 2, in an overall yield of
68% for two steps. 1H NMR (300 MHz, DMSO-d6) d 8.223 (s, 1H),
7.808 (d, J = 9.0, 2H), 7.256 (d, J = 9.0, 2H); ESI-MS: 250 [M+1]+;
HRESI-MS: m/z calcd for C11H9FN3O3 ([M+H]+) 250.1979; found
250.1983.
6.5.11. 5-(4-Hydroxypiperidine-1-carbonyl)-N-(pyridin-2-yl)-
1H-imidazole-4-carboxamide (9)
Piperidin-4-yl acetate (27.7 mg, 0.213 mmol) and 18a (60 mg,
0.194 mmol) in DMF (3.0 mL) were heated to 130 °C for 30 min
in a CEM microwave oven. The reaction mixture was allowed to
rt and the DMF was removed under vacuum. The residue was dis-
solved in 1 N LiOH (2 mL) and THF (2 mL). The solution was stirred
at rt for 6 h. After the reaction was completed, the pH of the aque-
ous phase was adjusted to 3 and was extracted with DCM
(10 mL ꢀ 2). The DCM was removed under vacuum, the residue
was purified by column chromatography on silica gel to give a
white solid 40.9 mg, (yield: 67% in two steps): 1H NMR
(300 MHz, CDCl3) d 13.44 (s, 1H), 12.91–12.25 (s, 1H), 8.37 (d,
J = 4.2 Hz, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.94 (s, 1H), 7.85 (t,
J = 7.8 Hz, 1H), 7.21–7.12 (m, 1H), 4.85–4.76 (m, 1H), 4.15–4.03
(m, 1H), 3.86–3.73 (m, 1H), 3.42–3.27 (m, 4H), 1.95–1.68 (m,
2H), 1.54–1.29 (m, 2H). ESI-MS: 316.2 [M+1]+; HRESI-MS: m/z
calcd for C15H18N5O3 ([M+H]+) 316.1410; found 316.1400.
6.5.6. 4-((4-Fluorobenzyl)carbamoyl)-1H-imidazole-5-
carboxylic acid (3)
The title compound was obtained from 17 (100 mg,
0.233 mmol) and p-fluorobenzylamine (58.3 mg, 0.466 mmol) as
described above in the method B. Pale yellow solid, yield 62%; 1H
NMR (300 MHz, DMSO-d6) d 8.060 (s, 1H), 7.363 (d, J = 7.8, 2H),
7.162 (d, J = 7.8, 2H), 4.494 (s, 2H); ESI-MS: 264 [M+1]+; HRESI-
MS: m/z calcd for C12H11FN3O3 ([M+H]+) 264.2245; found
264.2238.
6.5.12. 5-(Piperazine-1-carbonyl)-N-(pyridin-2-yl)-1H-
imidazole-4-carboxamide (10)
6.5.7. 4-(Pyridin-2-ylcarbamoyl)-1H-imidazole-5-carboxylic
acid (5)
The title compound was obtained from 18a (100 mg,
0.233 mmol) and piperazine (38.4 mg, 0.466 mmol) as described
above in the method C. white solid, yield 87%; 1H NMR
(300 MHz, CDCl3) d 8.37 (d, J = 3.9 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H),
7.94 (s, 1H), 7.85 (t, J = 7.7 Hz, 1H), 7.21–7.12 (m, 1H), 3.90–3.73
(m, 2H), 3.70–3.60 (m, 2H), 2.85–2.76 (m, 2H), 2.76–2.68 (m,
2H). ESI-MS: 301.2 [M+1]+; HRESI-MS: m/z calcd for C14H17N6O2
([M+H]+) 301.1413; found 301.1417.
The title compound was obtained from 17 (100 mg,
0.233 mmol) and 2-aminopyridine (84 mg, 0.466 mmol) as de-
scribed above in the method B. Pale yellow solid, yield 67%; 1H
NMR (300 MHz, DMSO-d6) d 8.281(s, 1H), 7.844(d, J = 11.7, 2H),
7.411(d, J = 11.7, 2H); 13C NMR (100 MHz, DMSO-d6) d 160.4,
150.7, 148.4, 138.5, 137.6, 137.5, 135.6, 129.8, 120.5, 114.4; ESI-
MS: 233 [M+1]+; HRESI-MS: m/z calcd for C10H9N4O3 ([M+H]+)
233.0675; found 233.0690.
6.5.13. N-(2-Hydroxyphenyl)-5-(morpholine-4-carbonyl)-1H-
imidazole-4-carboxamide (11)
6.5.8. 4-((4-Nitrophenyl)carbamoyl)-1H-imidazole-5-carboxylic
acid (6)
Morpholine (18.6 mg, 0.213 mmol) and 18c (80 mg, 0.194 mmol)
in DMF (3.0 mL) were heated to 130 °C for 30 min in a CEM micro-
wave oven. The reaction was allowed to cool and the DMF was re-
moved under vacuum. The residue was dissolved in EtOH (5 mL)
and 10 percent 20% Pd(OH)2/C was added thereto. The reaction
mixture was stirred at rt for 3 h under hydrogen atmosphere. After
completion of the reaction, the solution was filtered with a cellite
and the filtrate was distilled under a reduced pressure to afford the
title compound, which was purified by column chromatography on
silica gel to give a white solid 46.7 mg, (yield: 76.1% in two steps):
1H NMR (300 MHz, CDCl3) d 8.02–7.95 (m, 1H), 7.81 (s, 1H), 7.00–
6.95 (m, 1H), 6.86 (t, J = 1.4 Hz, 1H), 6.84–6.80 (m, 1H), 3.84–3.75
(m, 4H), 3.73–3.64 (m, 4H). ESI-MS: 317.2 [M+1]+; HRESI-MS: m/
z calcd for C15H17N4O4 ([M+H]+) 317.1250; found 317.1255.
The title compound was synthesized from 17 (100 mg,
0.233 mmol) and p-nitroaniline (64.4 mg, 0.466 mmol) as de-
scribed above in the method B. Pale yellow solid, yield 61%; 1H
NMR (300 MHz, DMSO-d6) d 8.298(s, 1H), 7.861(d, J = 9.0, 2H),
7.427(d, J = 9.0, 2H); ESI-MS: 277 [M+1]+; HRESI-MS: m/z calcd
for C11H9N4O5 ([M+H]+) 277.1331; found 277.1318.
6.5.9. 4-((4-Aminophenyl)carbamoyl)-1H-imidazole-5-
carboxylic acid (7)
The title compound was synthesized from 17 (100 mg,
0.233 mmol) and (9H-fluoren-9-yl)methyl (4-aminophenyl)carba-
mate (153.8 mg, 0.466 mmol) as described above in the method
B. Pale yellow solid, yield 72%; 1H NMR (300 MHz, DMSO-d6) d
8.362 (s, 1H), 8.267(d, J = 9.1, 1H), 7.804 (m, 2H), 7.106 (dd,
J = 5.4, 6.0, 1H); 13C NMR (100 MHz, DMSO-d6) d 161.22, 159.91,
137.68, 136.25, 133.12, 129.23, 127.93, 123.25, 122.44; ESI-MS:
247 [M+1]+; HRESI-MS: m/z calcd for C11H11N4O3 ([M+H]+)
247.0831; found 247.0815.
6.5.14. N-(2-Hydroxyphenyl)-5-(4-hydroxypiperidine-1-
carbonyl)-1H-imidazole-4-carboxamide (12)
Piperidin-4-yl acetate (27.7 mg, 0.213 mmol) and 18c (80 mg,
0.194 mmol) in DMF (3.0 mL) were heated to 130 °C for 30 min
in a CEM microwave oven. The reaction was allowed to cool and
the DMF was removed under vacuum. The residue was dissolved
in 1 N LiOH (2 mL) and THF (2 mL). The solution was stirred at rt.
After the reaction was completed, the pH of the aqueous phase
was adjusted to 3 and was extracted with DCM (10 mL ꢀ 2). The
combined organic phases were evaporated in vacuum, and the res-
idue was dissolved in EtOH (5 mL). 10 percent 20% Pd(OH)2/C was
added thereto, and the reaction mixture was stirred at rt for 3 h un-
der hydrogen atmosphere. After completion of the reaction, the
resulting solution was filtered with a cellite and distilled under a
reduced pressure to obtain the title compound, which was purified
by column chromatography on silica gel to give a white solid
36.2 mg, (yield: 56.7% in three steps): 1H NMR (300 MHz, CDCl3)
d 8.31–8.09 (m, 1H), 7.87 (s, 1H), 7.01–6.87 (m, 2H), 6.85–6.76
(m, 1H), 4.80 (s, 1H), 4.09 (s, 1H), 3.77 (s, 1H), 3.38–3.29 (m, 4H),
6.5.10. General procedure for the preparation of unsymmetric
4,5-dicarboxamide 8 and 10. Method C. 5-(Morpholine-4-
carbonyl)-N-(pyridin-2-yl)-1H-imidazole-4-carboxamide (8)
Morpholine (18.6 mg, 0.213 mmol) and 18a (60 mg,
0.194 mmol) in DMF (3.0 mL) were heated to 130 °C for 30 min
in a CEM microwave oven. The reaction was allowed to cool and
the DMF was removed under vacuum, the residue was purified
by column chromatography on silica gel to give a white solid
47.3 mg, (yield: 81%): 1H NMR (300 MHz, CDCl3) d 13.51 (s, 1H),
12.67 (s, 1H), 8.37 (d, J = 4.9 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.96
(s, 1H), 7.91–7.81 (m, 1H), 7.16 (dd, J = 6.8, 5.4 Hz, 1H), 3.82–3.68
(m, 4H), 3.68–3.59 (m, 2H), 3.40–3.28 (m, 2H). ESI-MS: 302.3
[M+1]+; HRESI-MS: m/z calcd for C14H16N5O3 ([M+H]+) 302.1253;
found 302.1264.